Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Insight - Drug repositioning: a new strategy for success

This article was originally published in Scrip

Executive Summary

The repositioning of drugs for new clinical indications is becoming an increasingly prominent development strategy because it can reduce development risk as well as both the time and investment required to bring a product to market. Previously exclusive to pharmaceutical companies working to expand the applications of their marketed drugs, repositioning (also known as repurposing, reprofiling, therapeutic switching, or developing 'second use' indications) has emerged as an industry in its own right, encompassing both technology and drug companies. Today, companies involved in repositioning are charging for their services, establishing collaborative agreements and using the strategy to develop their own pipelines.

You may also be interested in...



Melior, Bukwang Seek Diabetes Edge With Novel Insulin Sensitizer

MLR-1023, a repositioned oral compound being developed for type 2 diabetes by Melior and Bukwang, is set to move into Phase IIb in the US and South Korea, and the firms are looking to its novel mechanism of action, improved tolerability and efficacy to carve a niche in a highly competitive sector.

Market Insight - Antidepressants: life cycle management to the rescue?

Life cycle management approaches include the development of new formulations of drugs (for example, advanced delivery systems, metabolites or isomers) in order to improve the clinical performance and extend the patent life of well established drugs. In today's cost-containment environment, however, payers and physicians are challenging this strategy by asking tougher questions, such as ‘is the new drug superior to its predecessor?" and ‘if there is a benefit, is it marginal, or is it large enough to justify a significantly higher price, when compared with all prescription antidepressants?'

Market Insight - Can ageing be slowed to prevent disease?

The idea of extending the human lifespan has long fascinated the public and challenged scientists. Funding for research into ageing processes, and the R&D of therapeutics to slow them, is increasing. Recent findings suggest that progress has been made, motivated in part by the rapid growth of elderly populations that might benefit from such advances. Furthermore, economists predict that many countries may face bankruptcy by 2050 (or earlier) because of rising healthcare expenditures associated with care of the elderly.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC030839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel